{"entity":{"id":"nct04024696","kind":"trial","name":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients","aka":[],"tldr":"A phase 1/2 trial of Abexinostat in hodgkin lymphoma and non-hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.","summary":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients is a phase 1/2 interventional study registered as NCT04024696 by Xynomic Pharmaceuticals, Inc., with 12 participants enrolled, started 2020-01-08 and due to reach its primary completion in 2024-12-30. Interventions recorded: Abexinostat. Conditions listed: Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04024696","url":"https://clinicaltrials.gov/study/NCT04024696"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["abexinostat"],"companies":["xynomic-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04024696","phase":"1/2","setting":"An Open-Label, Non-Randomized Clinical Study to Evaluate Pharmacokinetic (PK) Profiles, Safety, and Tolerability of Abexinostat Monotherapy in Patients With Non-Hodgkin's Lymphoma Who Have Failed Standard of Care","sponsor":"Xynomic Pharmaceuticals, Inc.","participation":[{"nct":"NCT04024696","source":"https://clinicaltrials.gov/study/NCT04024696","fetchedAt":"2026-10-07T16:53:12.810Z","studySha256":"b3ee02c0aa15edf5f1527c9493d366eac21f929417042ff21ba7cdbb23e2d9c9","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-04-10","leadSponsor":"Xynomic Pharmaceuticals, Inc.","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"65 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":12,"enrolmentType":"ACTUAL","siteCount":4,"recruitingSiteCount":0,"countries":["China"]}],"started":"2020-01-08","startedType":"actual","enrolled":12,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04024696/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"abexinostat","kind":"drug","name":"Abexinostat","route":"/drugs/abexinostat/"}],"company":[{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/"}]}}